California DCC Says DEA Won't Answer Rescheduling Questions

Federal Silence Stalls State Planning

The DEA hasn't provided guidance to California or other state regulators on how the Schedule III reclassification will interact with existing state cannabis frameworks. Nicole Elliott, director of the Department of Cannabis Control, said in a September 18 statement that repeated requests for clarification have gone unanswered since the rescheduling notice of proposed rulemaking was published earlier this year.

California's 1,200+ licensed operators don't know whether Schedule III status will trigger new compliance obligations, alter banking access, or change enforcement priorities under the Controlled Substances Act. The lack of federal direction creates operational uncertainty across the board.

Key Unanswered Questions

State officials are seeking clarity on at least four operational issues: whether state licenses will satisfy federal distribution requirements, how 280E tax treatment changes, what happens to existing criminal records, and whether interstate commerce becomes permissible. The DEA hasn't addressed any of these questions in public guidance or direct communication with state agencies.

California isn't alone. Regulators in Colorado, Michigan, and New York have reported similar communication gaps, according to industry sources familiar with interstate regulatory coordination calls.

Schedule III Timeline Remains Unclear

The DEA's rescheduling process entered the public comment period in May 2026, with a final rule expected by late 2026 or early 2027. The agency hasn't published a timeline for responding to state-level inquiries or issuing implementation guidance for state-legal markets.

Elliott noted that California's regulatory framework was built around Schedule I status. Big change. Adapting state rules to a Schedule III regime requires lead time the DCC doesn't currently have, and without federal signals the agency can't finalize contingency plans.

THCA and Hemp Loopholes Complicate the Picture

The rescheduling debate hasn't addressed whether THCA—delta-9-tetrahydrocannabinolic acid, the non-intoxicating precursor that converts to THC through decarboxylation—will remain federally unscheduled under the 2018 Farm Bill's definition of hemp. If THCA stays legal at the federal level while delta-9 THC moves to Schedule III, California and other states face a bifurcated market where hemp-derived THCA products compete with state-licensed cannabis.

Elliott's office has asked the DEA to clarify the legal status of THCA, delta-8 THC, and other cannabinoids post-rescheduling. No response yet.

What Comes Next

California plans to submit formal written questions to the DEA through the Federal Register comment process and will coordinate with other states through the Cannabis Regulators Association. Elliott said the DCC will proceed with state-level contingency planning but can't finalize new rules without federal input.

The next signal: whether the DEA addresses state concerns in its final rescheduling rule or leaves implementation details to post-rule guidance. For more on the federal rescheduling process, see the CannIntel topic hub on DEA Cannabis Rescheduling.